Identification

Name
Butylscopolamine
Accession Number
DB09300  (DB11535)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

Butylscopolamine is a peripherally acting antimuscarinic, anticholinergic agent. It is used to treat pain and discomfort caused by abdominal cramps, menstrual cramps, or other spasmodic activity in the digestive system. It is also effective at preventing bladder spasms. It is not a pain medication in the normal sense, since it does not directly affect pain, but rather works to prevent painful cramps and spasms from occurring. It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system.

Structure
Thumb
Synonyms
  • N-butylscopolammonium
  • N-butylscopolammonium cation
  • N-butylscopolammonium ion
Product Ingredients
IngredientUNIICASInChI Key
Butylscopolamine bromide0GH9JX37C8149-64-4HOZOZZFCZRXYEK-GSWUYBTGSA-M
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BuscopanTablet10 mgOralSanofi Aventis1976-12-31Not applicableCanada
BuscopanLiquid20 mgIntramuscular; Intravenous; SubcutaneousSanofi Aventis1976-12-31Not applicableCanada
Buscopan Sup 10mgSuppository10 mgRectalBoehringer Ingelheim (Canada) Ltd Ltee1976-12-312001-07-30Canada
Hyoscine Butylbromide Injection Sandoz StandardSolution20 mgIntramuscular; Intravenous; SubcutaneousSandoz Canada Incorporated1997-08-25Not applicableCanada
Categories
UNII
2Z3E1OF81V
CAS number
7182-53-8
Weight
Average: 360.473
Monoisotopic: 360.21693487
Chemical Formula
C21H30NO4
InChI Key
YBCNXCRZPWQOBR-WVHCHWADSA-N
InChI
InChI=1S/C21H30NO4/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14/h5-9,15-20,23H,3-4,10-13H2,1-2H3/q+1/t15-,16-,17-,18+,19-,20+,22?/m1/s1
IUPAC Name
(1R,2R,4S,5S,7R)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium
SMILES

Pharmacology

Indication

Used to treat abdmoninal cramping and pain [FDA Label].

Structured Indications
Pharmacodynamics

Scopolamine butylbromide is a muscarinic antagonist which acts to prevent acetylcholine-stimulated contraction of smooth muscle in the gastrointestinal tract [1].

Mechanism of action

Scopolamine butylbromide binds to muscarinic M3 receptors in the gastrointestinal tract [1]. This prevents acetycholine from binding to and activating the receptors which would result in contraction of the smooth muscle. The inhibition of contraction reduces spasms and their related pain during abdominal cramping.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M3
antagonist
Human
UMuscarinic acetylcholine receptor M2
antagonist
Human
Absorption

Scopolamine butylbromide has extremely low oral bioavailability with only 0.25-0.82% reaching systemic circulation [1]. Peak plasma concentration is reached 0.25-2 hours. Scopolamine butylbromide does not cross the blood brain barrier.

Volume of distribution

The volume of distribution is 128 liters [1].

Protein binding
Not Available
Metabolism

Metabolism occurs mainly through hydrolysis of the ester bond [1]. The metabolites are not considered to be significantly active.

Route of elimination

Mainly eliminated in the feces (69.7%) with very little in the urine (4.4%) [1]. Only 2.8% is eliminated via the bile owing to scopolamine butylbromide's poor absorption.

Half life

The half life of elimination is 1-5 hours [1].

Clearance

Total clearace is 1.2 liters per minute [1].

Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumButylscopolamine may increase the anticholinergic activities of Aclidinium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Scopolamine butylbromide.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Atracurium.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Scopolamine butylbromide.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Scopolamine butylbromide.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Scopolamine butylbromide.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine butylbromide.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Scopolamine butylbromide.Approved
BezitramideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Scopolamine butylbromide.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Scopolamine butylbromide.Experimental
Botulinum Toxin Type AScopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BScopolamine butylbromide may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Scopolamine butylbromide.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine butylbromide.Approved
CimetropiumButylscopolamine may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine butylbromide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Scopolamine butylbromide.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Scopolamine butylbromide.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Scopolamine butylbromide.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Scopolamine butylbromide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Scopolamine butylbromide.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with DPDPE.Experimental
DronabinolScopolamine butylbromide may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Edrophonium.Approved
EluxadolineScopolamine butylbromide may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Emepronium.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Scopolamine butylbromide.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Etybenzatropine.Experimental
FentanylThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Scopolamine butylbromide.Approved
GalantamineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Scopolamine butylbromide.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Butylscopolamine is combined with Glucagon recombinant.Approved
GlycopyrroniumScopolamine butylbromide may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Scopolamine butylbromide.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Scopolamine butylbromide.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Scopolamine butylbromide.Approved
IpidacrineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine butylbromide.Approved
IsoflurophateThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Scopolamine butylbromide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Ketobemidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Mazaticol.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine butylbromide.Approved
MefloquineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Scopolamine butylbromide.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine butylbromide.Approved
Methylscopolamine bromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Scopolamine butylbromide.Approved
MianserinMianserin may increase the anticholinergic activities of Scopolamine butylbromide.Approved, Investigational
MinaprineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Morphine.Approved, Investigational
NabiloneScopolamine butylbromide may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Scopolamine butylbromide.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Otilonium.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxitropium.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Scopolamine butylbromide.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Scopolamine butylbromide.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Scopolamine butylbromide.Approved
ParaoxonThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Scopolamine butylbromide.Approved
PethidineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Scopolamine butylbromide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Scopolamine butylbromide.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Scopolamine butylbromide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Scopolamine butylbromide.Approved
Potassium ChlorideButylscopolamine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Scopolamine butylbromide.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Scopolamine butylbromide.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Scopolamine butylbromide.Approved
PropiverineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Propiverine.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Scopolamine butylbromide.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Scopolamine butylbromide.Approved
RamosetronScopolamine butylbromide may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Scopolamine butylbromide.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Scopolamine butylbromide.Approved
SufentanilThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Butylscopolamine.Approved, Investigational
TacrineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tilidine.Experimental
TiotropiumButylscopolamine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Scopolamine butylbromide.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine butylbromide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Scopolamine butylbromide.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Scopolamine butylbromide.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Scopolamine butylbromide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Scopolamine butylbromide.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Scopolamine butylbromide.Approved
UmeclidiniumButylscopolamine may increase the anticholinergic activities of Umeclidinium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Scopolamine butylbromide.Approved
Food Interactions
Not Available

References

General References
  1. Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57. [PubMed:17547475]
External Links
KEGG Drug
D01451
PubChem Compound
6852391
PubChem Substance
310265192
ChemSpider
21782131
ChEBI
32123
ChEMBL
CHEMBL1618102
Wikipedia
Butylscopolamine
ATC Codes
A03BB01 — ButylscopolamineA03DB04 — Butylscopolamine and analgesics
AHFS Codes
  • 12:08.08 — Antimuscarinics Antispasmodics
FDA label
Download (459 KB)
MSDS
Download (182 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentRenal Colic1
2CompletedTreatmentColic1
2CompletedTreatmentGastrointestinal Diseases1
2, 3CompletedPreventionEndoscopy1
3CompletedPreventionBile Duct Diseases / ERCP / Pancreatic Diseases1
3CompletedTreatmentIntestinal Diseases1
3RecruitingTreatmentAcute Abdomen / Children1
3RecruitingTreatmentProlonged Labour1
4CompletedPreventionFamily Planning1
4CompletedPreventionPain Relief With HSG1
4CompletedTreatmentEmergency / Indigestion / Pain1
4CompletedTreatmentVaginal Delivery1
4RecruitingSupportive CareVaginal Delivery1
4RecruitingTreatmentAbdominal Cramps1
Not AvailableNot Yet RecruitingDiagnosticHysteroscopic Surgery / Postoperative pain1
Not AvailableRecruitingDiagnosticConstipation - Functional / Irritable Bowel Syndrome Characterized by Constipation1
Not AvailableRecruitingDiagnosticGastrointestinal Imaging With pCLE1
Not AvailableUnknown StatusTreatmentInfertilities1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous; Subcutaneous20 mg
TabletOral10 mg
SuppositoryRectal10 mg
SolutionIntramuscular; Intravenous; Subcutaneous20 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00201 mg/mLALOGPS
logP0.79ALOGPS
logP-1.9ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.06 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity109.51 m3·mol-1ChemAxon
Polarizability39.82 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57. [PubMed:17547475]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs. 2007;67(9):1343-57. [PubMed:17547475]

Drug created on November 10, 2015 13:46 / Updated on December 11, 2017 13:02